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Abstract
Background: Mycoplasma pneumoniae (Mpn), Chlamydia pneumoniae (Cpn), and Legionella
pneumophila (Lpn) can cause both epidemic and endemic occurrences of acute respiratory
disease and are responsible for up to 22% of cases of community acquired pneumonia. Due to
the limited availability of FDA-approved molecular diagnostic assays, we developed and evaluated
a multiplexed Real-time PCR assay for the detection of these agents in two respiratory specimen
types on the Luminex ARIES® instrument. The instrument provides for nucleic acid extraction plus
PCR amplification and target detection in the same cassette. The ARIES® instrument generates a
cycle threshold value and a confirmatory melt curve value for each reaction, including results for
an internal sample processing control. The limit of detection for Mpn, Cpn and Lpn, was 100 CFU/
mL, 1000 CFU/mL and 100 CFU/mL, respectively. In addition, accuracy, precision, specificity and
stability studies were conducted to validate the assay for diagnostic use. Between November 2016
and June 2017, a total of 836 patient specimens were processed in our reference laboratory, with six
positive Mpn and two positive Lpn. No specimens were positive for Cpn during this time period. The
availability of a robust multiplex PCR assay greatly enhances the ability to rapidly diagnose infections
caused by these three agents causing atypical pneumonia.
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Introduction
Respiratory infections caused by Legionella pneumophila
(Lpn), Mycoplasma pneumoniae (Mpn) and Chlamydia
pneumoniae (Cpn) may account for up to 22% of all cases of
community-acquired pneumonia (CAP) worldwide [1]. These
infections may occur in outbreak situations or as sporadic
cases.
Often referred to as etiologic agents of “atypical
pneumonia”, Lpn, Mpn and Cpn are not detected during routine
microbiologic work-up, and typically require special testing
requests. Respiratory fluoroquinolones, or macrolide plus beta
lactam class antibiotics, are used to treat patients presenting
with community acquired pneumonia initially; thus, a rapid and
accurate diagnosis allows for targeted antimicrobial therapy [2].

agents, molecular detection in respiratory specimens is the
preferred test for rapid diagnosis [12]. This will most often
lead to the initiation of appropriate antimicrobial therapy [1].
While macrolides remain the treatment choice for CAP due to
Mpn, it is worth noting that resistance has been found in the
USA. In a study published in 2015, 13.2% of 91 positive patient
specimens demonstrated resistance to macrolides such as
erythromycin [13]. Emerging resistance with Mpn reinforces
the need for rapid and accurate diagnostics performed directly
from respiratory specimens. In this way, treatment failures
can be effectively managed based on accurate and specific
identification of one or more pathogens.

Diagnosis of these agents has undergone an evolution from
detection by isolation in culture [3-5], serologic methods
[6], detection of urinary antigen for Lpn [7] and eventually,
molecular detection in respiratory specimens [8]. Molecularbased assays were initially reported for Lpn by Edelstein et. al.,
[9] in 1986, for Mpn by Bernet et. al., in 1989 [10] and for Cpn
by Holland et. al. in 1990 [11]. Since that time, additional assays
have been described and studies have concluded that due to the
lower level of sensitivity of non-molecular detection of these

Subsequently, these three assays have been described in
multiplexed format by several investigators [14, 15] and two
of these targets, Mpn and Cpn, are currently included in two
FDA-cleared assays, the FilmArray Respiratory Panel (Biofire
Diagnostics, Salt Lake City, UT) and the NxTAG Respiratory
Pathogen Panel (Luminex, Inc., Austin, TX). Recently, CMS has
published draft statements about reducing reimbursements for
highly multiplexed panels such as these [16], making smaller,
targeted panels more appealing to laboratories and health care
providers.
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We report here the development and evaluation of a
multiplexed PCR assay for the detection of Mpn, Cpn and Lpn
in oropharyngeal swabs (OP) and broncho-alveolar lavage
(BAL) fluid specimens on the Luminex ARIES® instrument. The
ARIES® is a stand-alone, open-platform instrument in which the
assay uses Multicode®-RTx Technology (Luminex, Inc., Austin,
TX) with the synthetic base pair isoC:isoG in a probe-free PCR
assay. Because of the hydrogen bonding pattern between these
two synthetic bases, they can only bind to each other, adding
specificity to the DNA amplification process. This closed system
greatly simplifies the process of extraction, amplification and
detection within a single cassette while remaining robust for
diagnostic testing purposes.

Methods
Reagents: Proprietary MultiCode-Rtx® primer pairs for Mpn,
Lpn and Cpn (Part numbers: 3927, 3926 and 3925) were
obtained from Luminex. Mouse Hepatitis Virus Control Primer
Set 5 (MHV5, proprietary sequence, Part Number: 3806) was
used to amplify the Sample Processing Control (SPC, used to
confirm extraction, amplification and to detect PCR inhibition).
The melt calibrator function allowed for calibration of detected
melting temperatures (Tm) in the cassette based on MHV5
amplification. ReadyMix® tubes (Part Number 3697, Luminex,
Austin, TX) contain all reagents needed to run PCR on the
Luminex ARIES® instrument. SnotBuster® was purchased from
COPAN (Catalog number 097CE.A, Murietta, CA). Universal
Transport Media (UTM) and flocked swabs were purchased
from Quidel/Diagnostic Hybrids (Part Number 402C, San
Diego, CA).
Primer Pool Preparation: The four primer sets (Mpn, Lpn, Cpn
and MHV5) were purchased in 100 μL aliquots. Once thawed,
primers were given a quick spin and equal volumes of each
primer were combined to make the multiplex primer set. Pooled
primers were stored at -20°C in aliquots of 80 μL.
Organisms: Mpn (ATTC®, Catalog number: 15531TT), Cpn
(titered clinical isolate) and Lpn (titered clinical isolate) were
used for sensitivity and precision studies. Mpn was grown as
described previously [17]. Cpn was propagated in Hep2C cells,
then harvested, purified and titered as described previously
[18]. Lpn was grown on Buffered Charcoal Yeast Extract (BCYE)
agar plates and colonies were suspended in saline. Suspensions
were adjusted to a 0.5 McFarland Standard (approximately
1.5x108 CFU/mL) prior to diluting in UTM for PCR studies.
Specimens: Sensitivity, accuracy, precision, stability and
specificity studies were assessed using BAL fluid and OP swabs
which were collected from healthy volunteers and patients with
pneumonia. These specimens were used as matrices after testing
negative for Mpn, Cpn and Lpn by both our laboratory-validated
PCR test and by the ARIES® PCR assay. For each PCR assay,
200 µL of OP swab specimens collected in universal transport
media were used. BAL fluid specimens were pre-treated with
SnotBuster® before loading into cassettes by adding 200 µL of
specimen to a 1.5 mL microtube and 200 µL of SnotBuster®,
then mixed by vortexing for 10 seconds. After incubating at
room temperature for 15 minutes, the SnotBuster® pre-treated
BAL fluid specimens were centrifuged using a Thermo-Fisher
mini centrifuge (mySPIN 6) at 2000 x g for one minute. After
centrifugation, 390 µL (to avoid any pelleted material) of the

pre-treated BAL supernatant was used for the PCR assay.
Cassette Preparation: Eight (8) µL of multiplex primer mix were
added to each ReadyMix® tube, then attached to the ARIES®
cassette. ARIES® Cassettes (Part Number: 50-10026, Luminex)
hold the extraction reagents and Sample Processing Control
(SPC). The samples to be tested were added to the cassette and
loaded onto the ARIES, then the extraction, PCR reaction, and
result generation proceeded automatically.
Sensitivity experiments: For sensitivity, the Limit of Detection
(LOD, or cutoff) was determined for three targets (Mpn, Cpn
and Lpn) in both BAL fluid and OP swab specimen types that
were negative by both PCR assays. Mpn, Cpn and Lpn were
spiked individually into each specimen type at concentrations
of 1 x 105 CFU/mL, 1 x 104 CFU/mL, 1 x 103 CFU/mL, 100 CFU/
mL, 10 CFU/mL, and 1 CFU/mL then tested as described above.
This sensitivity assay was conducted three times independently.
Accuracy experiments: For the accuracy study, archived patient
specimens that were tested previously using an in-house
validated laboratory-developed test (LDT) PCR assay were
tested on the ARIES® instrument. All the positive samples were
previously PCR-positive for Mpn, Lpn or Cpn in our laboratory
from patients for whom a pneumonia infection was detected
using the LDT PCR. Twenty-three (23) Mpn-positive samples
(either OP swab or BAL fluid specimens), nineteen (19) Lpnpositive samples (all BAL fluid specimens) and one Cpn-positive
patient BAL fluid specimen were tested. In addition, DNA from
eleven (11) different Cpn-positive patients was spiked into
ReadyMix® tubes for OP swab specimens, and DNA from ten
(10) Cpn-positive patients was spiked into ReadyMix® tubes
for BAL fluid specimens, then placed in the extraction cassette
containing negative specimen and tested. For negative controls,
thirteen (13) negative patient BAL fluid specimens and seven (7)
negative patient OP swab specimens were tested.
Precision experiments: Reproducibility studies to determine
precision were done using both BAL fluid and OP swab specimen
types for all three targets spiked with a concentration of 1 x 103
CFU/mL. One positive control containing all three targets (as
well as a negative control) were run on different days in order to
obtain ten successful runs with different operators for both OP
swab and BAL fluid specimen types previously determined to be
negative by both PCR assays.
Stability experiments: Specimen stability studies were
conducted by storage of spiked BAL fluid and OP swab specimen
types (1 x 103 CFU/mL, in duplicate) at 4°C, and these samples
were assayed daily for eight days.
Specificity experiments: Twelve bacterial organisms, including
Enterococcus faecalis, Escherichia coli, Staphylococcus
aureus, Proteus mirabilis, Aerococcus viridans, Streptococcus
agalactiae, Moraxella catarrhalis, Staphylococcus epidermidis,
Streptococcus pyogenes, Streptococcus pneumoniae, Klebsiella
pneumoniae and Burkholderia cepacia, kindly provided by
Dr. Alan Junkins, Norton Healthcare, Louisville, KY were
used for specificity determination in both OP swab and BAL
fluid specimens. Legionella bozemanii, L. pneumophila
Togus-1, L. pneumophila Bloomington-2, and L. pneumophila
Dallas 1E were provided by the laboratory of Dr. Richard
Miller, Environmental Safety Technologies. Louisville, KY L.
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pneumophila Knoxville (ATCC® 33153, strain type) and L.
pneumophila Philadelphia (ATCC® 33152, strain type) were
obtained from the American Type Tissue Collection (ATCC,
Manassas, VA). A single colony was selected from freshly
sub-cultured plates using a sterile loop; the loop was used
to inoculate two different specimen types determined to be
negative for Mpn, Cpn and Lpn (200 µL of OP swab or BAL
fluid). In addition, several respiratory viruses were tested in
OP and/or BAL matrices. Five clinical samples from patients
previously diagnosed with viral infections using the FilmArray®
Respiratory Virus Panel (BioFireDX, Salt Lake City, UT) were
tested. Titered respiratory virus samples from Zeptometrix
(Buffalo, NY) were tested, including Influenza A/H3 (Catalog
#0810238CF, Texas/50/12), Human Metapneumovirus
(Catalog #0810156CF, hMPV 3/Type B1), Coronavirus 229E
(Catalog #0810229CF), Adenovirus B (Catalog #0810062CF,
Type 3/Species B), and Influenza A/H1N1 (Catalog
#0810244CF, Brisbane/59/07), all at titers >105 and assayed for
Tissue Culture Infecive Dose (TCID50). OP swab and BAL fluid
specimens were tested in duplicate to assess specificity.
Data Analysis: MS Excel was used to calculate standard
deviations for replicate experiments, while MEDCALC
Diagnostic Test Evaluation was used to determine analytic
sensitivity and specificity [19]. The Luminex ARIES® instrument
used SYNCT® software and User Defined Protocol (UDP)
module to set assay parameters and interpret run results. The
SYNCT® software was installed on an external computer for
detailed data analysis and editing of Ct and Tm cutoff values.
After completing data analysis and PCR assay validation, the cut
off values were fixed and locked in the SYNCT® software assay
file. Next, the assay file was loaded on the ARIES® instrument
for subsequent diagnostic laboratory testing (Table 1). In order
for a specimen to be called positive for Lpn, Mpn or Cpn, the
following conditions had to be met:
1.
The SPC for any given specimen must have a valid Ct value
and Tm to exclude sample inhibition.
2. The specimen must have Ct and Tm values in the
established range for each organism.
Table 1 Amplification and Melt Curve Settings for ARIES®
Mycoplasma Chlamydia
pneumoniae pneumoniae

Legionella
pneumophila

S.No

Conditions

SPC

1

Amplification curve Ct Cut off

1-40.0

1-40.0

1-40

1-45

2

Melt curve Tm Cutoff (°C)

77.5±1.0
(76.5 to 78.5)

80.5±1.0
(79.5-81.5)

71.5±1.5
(70.0-73.0)

84.0±1.0
(81.5-86.5)

3

Melt curve Tm Peak Threshold
cutoff (DRFU)

-250,000

-800,000

-1,300,000

-100,000

DRFU=Change in relative fluorescent units

Results

Table 2 Assay Sensitivity for Mpn, Cpn and Lpn in BAL Specimens
CONC
Mpn
Ct Mpn Tm Cpn Ct Cpn Tm Lpn Ct Lpn Tm SPC Ct
(CFU/mL) in values
values
values values
values values values
BAL
(SD)
(SD)
(SD)
(SD)
(SD)
(SD)
(SD)
*MPN run
1x105
31.5
77.47
31.4
80.7
26.47
71.33
35.67
(0.82)
(0.06)
(1.39)
(0.10)
(0.84) (0.06)
(2.11)
1x104
35.07
77.53
33.33
80.7
30.50
71.43
35.90
(0.51)
(0.12)
(2.63)
(0.00)
(0.87) (0.21)
(0.70)
1x103
38.56
77.46
38.27
80.7
34.27
71.53
35.2
(0.15)
(0.15)
(1.14) (0.06)
(0.46)
(1.02)
(0.10)
1x102
40.04
77.45
40.35
ND
36.83
71.50
35.63
(0.21)
(0.07)
(2.35) (0.20)
(0.07)
(0.81)
1x101
ND
ND
ND
ND
37.75
71.10
36.6
(0.49) (0.14)
(1.37)
1x100
ND
ND
ND
ND
ND
ND
35.33
(1.08)

ND=Not Detected

SPC Tm
values
(SD)
*MPN run
84.03
(0.23)
83.90
(0.10)
83.9
(0.10)
83.9
(0.10)
83.83
(0.10)
83.93
(0.15)

Accuracy: Twenty-three of 23 previous Mpn-positive samples
were likewise positive with the ARIES® assay, giving a 100%
sensitivity (Table 3). Twenty-one different previously Cpnpositive patient (11 OP swab and 10 BAL fluids) samples were
positive using the ARIES® assay, giving a 100% accuracy (Table
3). All 19-previous positive Lpn-samples were positive using
the ARIES® system as well, giving a 100% sensitivity (Table 3).
All 19 patient samples negative for both BAL fluid and OP swab
specimen types were also negative using the ARIES® system,
but the SPC was positive for all samples, indicating there was no
inhibition of PCR (data not shown). Sensitivity and specificity
are shown in Table 3.
Table 3 Accuracy Results for the Mpn, Cpn and Lpn PCR Assay
Target Organism
(Specimen Type)

Expected
Positive

Observed
Positive

% Agreement

Mpn (10 OP, 1 BAL, and 12 23
BAL or OP, unspecified)
Cpn (11 OP, 10 BAL)
21

23

100

21

100

Lpn (19 BAL)

19

19

100

None (13 BAL, 7 OP)

0

0

100

% Sensitivity
(95% Confidence
Interval)
100
(85.18-100)
100
(83.89-100)
100
(82.35-100)
N/A

% Specificity
(95% Confidence
Interval)
100
(83.16-100)
100
(83.16-100)
100
(83.16-100)
N/A

OP=oropharyngeal swab; BAL= brocho-alveolar lavage fluid; N/A=Not applicable

Precision: Mpn, Cpn and Lpn (1 x 103 CFU/mL) were spiked
into either negative BAL fluid or OP swab samples and used
as positive controls by different laboratory technologists on
different days. Reproducibility of the resultant Ct and Tm values
for four targets (including the MHV5 SPC) did not change over
the course of the different testing periods by different operators.
The standard deviation (SD) for Mpn, Cpn and Lpn Ct values
were less than 2.5, and SD Tm values less than 0.15, on both
BAL fluid and OP swab specimens (Table 4). Negative controls
were negative for all three targets. All internal control results
(SPC) indicated no inhibition on either BAL or OP specimen
types/matrices (individual run data not shown).
Table 4 Precision Studies for the Mpn, Cpn and Lpn PCR Assay
CONC.
Mpn Ct* Mpn Tm#
(1000 CFU/mL) AVG (SD) AVG (SD)
BAL
31.47
77.44
(1.75)
(0.10)
OP
31.45
77.47
(0.89)
(0.12)

Cpn
Ct
AVG (SD)
33.40
(2.29)
32.80
(1.60)

Cpn Tm
AVG (SD)
80.67
(0.11)
80.68
(0.10)

Lpn Ct
AVG (SD)
32.16
(1.29)
31.63
(1.10)

Lpn Tm
AVG (SD)
71.21
(0.14)
71.26
(0.11)

SPC Ct
AVG (SD)
36.33
(1.54)
35.05
(1.49)

SPC Tm
AVG (SD)
83.88
(0.14)
83.88
(0.09)

*Ct=Cycle threshold; #Tm=Melt temperature

Sensitivity: Sensitivity was expressed as the cutoff for all three
targets. All three organisms were serially diluted ten-fold from
1 x 105 to 1 x 100 CFU/mL for these experiments. Results are
represented as mean ± standard deviation, from three replicate,
independent experiments. The cutoff results for Mpn, Cpn
and Lpn were 100 CFU/mL, 1000 CFU/mL and 100 CFU/mL,
respectively (Table 2). Table 2 shows only the cutoff values for
BAL fluid specimens, but similar results were observed with OP
swab specimens for each organism (data not shown).

Stability: Mpn, Cpn and Lpn (1 x 103 CFU/mL of each
organism) were spiked into both BAL fluid and OP swab
matrices and tested in duplicate for seven days, and in singlet on
day eight. After preparing the sample on day one, it was stored
in the refrigerator at 4°C (±2°C). The SD for all Ct values over
eight days was less than 1.5 for both specimen types. Expected
Ct and Tm values for each organism were observed each day of
testing, whether they were spiked into BAL fluid or OP swab
specimens (data not shown). Thus, specimens demonstrated
stability at refrigerated temperatures for up to eight days after
collection.
Specificity: Twelve different bacterial organisms and several
common respiratory viruses were spiked into BAL fluid and OP
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swab matrices and tested Mpn,Cpn and Lpn primers (Table
5). In addition, five specimens from patients diagnosed with
respiratory virus illnesses were tested using the Mpn, Cpn
and Lpn multiplex PCR assay. There was no cross-reactivity
observed, and the results demonstrated that these primers
were specific to Mpn, Cpn and Lpn. In addition, Legionella
pneumophila strains of various serotypes and Legionella
bozemanii were tested to gauge genus, species and serotype
detection (Table 5). We found that multiple serotypes of
Lpn were detected, but not L. bozemanii, indicating that L.
pneumophila serotypes other than 01 could be identified by this
assay.

control is positive for any target (Mpn, Cpn or Lpn), the ARIES®
result shows the positive sample amplification (Ct value) and
melt curve (Tm) data but will not show Ct and Tm values for the
SPC (positive control example, Figure 1B). This is hardcoded
in the software for ARIES® instrument. The SPC amplification
and melt curve including Ct and Tm values can be obtained from
SYNCT® software, when needed.

Table 5 Specificity Studies for the Mpn, Lpn and Cpn PCR assay
Organism

Matrix
OP

SPC Ct
Value
35.5

SPC Tm
Value
83.8

Results

E. faecalis
E. coli
S. aureus
P. mirabilis
A. viridans
S. agalactiae
M. catarrhalis
S. epidermidis
S. pyogenes
S. pneumoniae
K. pneumoniae
B. cepacia

OP
OP
OP
OP
OP
OP
OP
OP
OP
OP
OP

37.3
36.2
35.6
37.3
35.0
34.6
37.3
35.9
35.5
38.1
37.3

83.9
83.8
83.8
83.8
83.8
84.1
83.8
84.1
84.1
83.9
83.9

Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn

Influenza A/H1N1
OP
(Zeptometrix)
Influenza A/H3 (Zeptometrix) OP

33.5

84.2

Negative for Mpn, Cpn, Lpn

38

84.3

Negative for Mpn, Cpn, Lpn

Influenza A/H3
(clinical)
Rhinovirus/ Enterovirus
(clinical)
Parainfluenza-4 (clinical)
Human Metapneumovirus
(clinical)
Human Metapneumovirus
(Zeptometrix)
Coronavirus OC4 (clinical)

OP

33.4

83.8

Negative for Mpn, Cpn, Lpn

OP

35

83.5

Negative for Mpn, Cpn, Lpn

OP
OP

33
37.2

83.6
83.3

Negative for Mpn, Cpn, Lpn
Negative for Mpn, Cpn, Lpn

OP

34.3

84.3

Negative for Mpn, Cpn, Lpn

OP

32.9

83.6

Negative for Mpn, Cpn, Lpn

Coronavirus 229E
(Zeptometrix)
Adenovirus 3/B
(Zeptometrix)
L. bozemanii

OP

33.5

84.2

Negative for Mpn, Cpn, Lpn

OP

31.7

84.3

Negative for Mpn, Cpn, Lpn

OP

33.6

83.8

L. pneumphila Togus-1;
Serogroup 02

OP

33.2

84.4

L. pneumophila
Bloomington-2; Serogroup
03
L. pneumonphila Dallas 1E;
Serogroup 05

OP

38.3

84.4

OP

38.5

83.4

L. pneumophila Knoxville;
Serogroup 01 (ATCC®
33153)
L. pneumophila
Philadelphia; Serogroup 01
(ATCC® 33152)

OP

38.8

84.4

OP

35.4

84.3

Negative for Mpn, Cpn,
Lpn
Negative for Mpn, Cpn,
Positive for Lpn (Ct
26.9/Tm 72)
Negative for Mpn, Cpn,
Positive for Lpn (Ct
22.4/Tm 71.4)
Negative for Mpn, Cpn,
Positive for Lpn (Ct
23.7/Tm 71.9)
Negative for Mpn, Cpn,
Positive for Lpn(Ct
19.8/Tm 71.5)
Negative for Mpn, Cpn,
Positive for Lpn(Ct
20.4/Tm 72)

Negative for Mpn, Cpn, Lpn

Performance with Clinical Specimens: Between
November 2016 and June 2017, a total of 836 patient specimens
were processed in our reference laboratory, with six positive
Mpn and two positive Lpn, giving a 0.72% positivity rate
(data not shown). No specimens had detectable Cpn. It was
noteworthy that samples rarely had to be retested due to invalid
results on the ARIES® instrument. Out of 1064 specimens tested
with the multiplex Mpn, Lpn and Cpn PCR assay, only 50 invalid
results occurred, giving a 4.7% invalid rate. When respiratory
samples did give invalid results, it was typically in BAL fluid
specimens with excessive blood or mucus, and diluting 1:2 or 1:4
with saline prior to re-testing gave valid results.
Example readout from ARIES® instrument: The SPC
must show the expected amplification and melt curve values (Ct
and Tm values) in patient samples that are negative (negative
control example, Figure 1A). If the patient sample or positive

Figure 1A Negative control result. Sample data from ARIES® instrument
with a negative control illustrating the amplification curve and melt
temperature for the internal control (SPC).

Figure 1B Positive control result. Sample data from ARIES® instrument
with a positive control illustrating the amplification curve and melt
temperature for Mpn, Cpn, and Lpn (SPC).

Discussion
The Luminex ARIES® instrument performs extraction and
generates PCR amplification and melt curves for each target
organism, plus the sample processing control, in a single
cassette. After addition of primers to ReadyMix® and specimen
to the cassette, the PCR amplification is completed in two
hours. Due to the limited availability of FDA-approved assays
that detect a small panel of atypical pneumonia organisms,
we present here the results of our laboratory validation of this
multiplex PCR assay that detects Mpn, Cpn and Lpn.
The established limits of detection for Mpn, Cpn and Lpn were
100 CFU/mL, 1000 CFU/mL and 100 CFU/mL, respectively
for both BAL and OP specimen types. This is similar sensitivity
to previously published studies using NP swabs [20] or NP
aspirates [21] in a multiplex PCR assay for Mpn, Cpn and Lpn
targets. For example, Miyashita et al. [20] found using their
multiplex PCR assay with a Micro-Chip Electrophoresis Analysis
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System, they could detect 100 copies per mL of Mpn, Cpn and
Lpn. When they tested 208 patients with community acquired
pneumonia using nasal swabs, the multiplex PCR assay detected
14/15 patients with Cpn, 10/10 with Mpn and 8/8 with Lpn
infections [20]. Similarly, Lam et al demonstrated a sensitivity
range of 1000 to 10,000 CFU/mL with a multiplex nested PCR
assay on the ABI FAST® PCR system [21]. Using 303 clinical
specimens (NP aspirates), they found a 48.5% positivity rate for
detecting Mpn, Cpn, Lpn or Adenovirus [21]. When previously
positive specimens were tested on the ARIES® system with the
PCR assay described here, each organism was correctly detected
compared to the results from the prior test platform used in
our laboratory, giving 100% sensitivity. Precision results were
excellent when the same specimens were tested on different
days by different testing personnel, as indicated by very small
standard deviations.
A panel of twelve different bacterial organisms and several
common respiratory viruses were tested using BAL fluid and OP
swab matrices. There was no cross-reactivity observed, thereby
demonstrating that these primers were specific to Mpn, Cpn and
Lpn. Because we tested L. pneumophila strains representing
serogroups 01, 02, 03, and 05, as well as L. bozemanii, we
demonstrated primer specificity for L. pneumophila; however,
we observed broader detection than L. pneumophila urine
antigen assays that target only serogroup 01. Finally, stability
studies indicated that after storage for eight days at 4°C, positive
specimens processed by the ARIES® instrument were detected.
Future studies could address the stability at -20°C and -80°C for
long-term specimen storage.
Taken as a whole, these results indicate that the Luminex
ARIES® PCR assay is quite robust. During the validation and
subsequent use as a diagnostic PCR assay, a few limitations
were noted. For BAL fluid specimens, excess mucus was found
to cause invalid results on rare occasions (50/1064, or 4.7%).
In these cases, diluting the specimen prior to mixing with
SnotBuster® and re-running the diluted specimen eliminated
the inhibition observed in the initial specimen. This was not
observed with OP swab specimens, which are typically free of
excess mucus. The Luminex ARIES® instrument uses SYNCT®
software to set parameters and interpret run results. Mastery
of this software requires dedicated time and effort; however,
technical support, assistance and training is available from
the manufacturer.
Finally, the ARIES® instrument uses
universal cycling conditions to facilitate multiplex PCR assay
development. If cycling conditions need to be changed for a
particular assay, they can be modified, but then separate assays
would need to be performed using different modules on the
ARIES® instrument.
The data presented here illustrate the performance
characteristics of a multiplex PCR assay for three agents of
atypical pneumonia. The MultiCode-Rtx® chemistry enables the
detection of almost any nucleic acid target due the highly specific
binding of IsoC and IsoG base pairs, without the need for an
additional fluorescent-tagged oligo or probe. The format is an
improvement over previously published processes due to the
elimination of a separate extraction step for clinical specimens.
Furthermore, due to the combination of ReadyMix® tubes and
cassettes used by the ARIES® instrument, minimal technologist
time is required because extraction, amplification and detection
occur within the cassette. This format reduces risk of cross-

contamination and amplicon contamination significantly and
provides both a Ct value and a melt curve value, adding specificity
to the assay. The ARIES® system is easy to use with Luminex
analyte specific reagents (ASR). Luminex application specialists
provide general guidance to aid in new assay development,
which is extremely valuable to smaller clinical laboratories with
limited resources. As an open PCR platform with the capacity to
design primers for multiple targets as well as internal controls,
this system offers flexibility for laboratories. This feature
is important during a time when reimbursement for highly
multiplexed assays is at risk [16], and more targeted panels
(like the atypical pneumonia assay described here) are favored
currently. In the current climate, it is critical that laboratories
calculate cost per test versus reimbursement, either through
third party insurance or direct billing for laboratory services, to
remain viable. Open platforms, such as the ARIES® system, can
help lower direct costs in the face of declining reimbursements.
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